Attenuation of the side effect profile of regadenoson: a randomized double-blind placebo-controlled study with aminophylline in patients undergoing myocardial perfusion imaging and have severe chronic kidney disease—the ASSUAGE-CKD trial
Authors:
- 11 December 2012
- journal article
- research article
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- Vol. 29 (5) , 1029-1037
Abstract
A subgroup analysis of the ASSUAGE trial suggested that the standardized intravenous aminophylline administration following regadenoson-stress leads to substantial attenuation of regadenoson adverse-effects in patients with severe chronic kidney disease (CKD). In a randomized, double-blinded, placebo-controlled clinical trial of patients with stage 4 and 5 CKD, we compared the frequency and severity of regadenoson adverse-effects in those who received 75 mg of intravenous aminophylline versus a matching placebo administered 90 s post-radioisotope injection. Consecutive 300 patients with severe CKD (36 % women; 86 % end-stage renal disease; age 55 (±13) years) were randomized to receive aminophylline (n = 150) or placebo (n = 150). In the aminophylline arm, there was 65 % reduction in the incidence of the primary endpoint of diarrhea (9 (6.0 %) vs. 26 (17.3 %), P = 0.002), 51 % reduction in the secondary endpoint of any regadenoson adverse-effect (47 (31.3 %) vs. 96 (64 %), P < 0.001) and 70 % reduction in headache (16 (10.7 %) vs. 54 (36 %), P < 0.001). The stress protocol was better tolerated in the aminophylline group (P = 0.008). The quantitative summed difference score, as a measure of stress-induced ischemic burden, was similar between the study groups (P = 0.51). In conclusion, the routine standardized administration of intravenous aminophylline in patients with severe CKD substantially reduces the frequency and severity of the adverse-effects associated with regadenoson-stress without changing the ischemic burden. [NCT01336140]Keywords
This publication has 20 references indexed in Scilit:
- A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney diseaseJournal of Nuclear Cardiology, 2012
- Racial differences in chronic kidney disease (CKD) and end-stage renal disease (ESRD) in the United States: a social and economic dilemmaClinical Nephrology, 2011
- Effects of Age, Gender, Obesity, and Diabetes on the Efficacy and Safety of the Selective A2A Agonist Regadenoson Versus Adenosine in Myocardial Perfusion ImagingJACC: Cardiovascular Imaging, 2008
- Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trialJournal of Nuclear Cardiology, 2007
- Regadenoson Pharmacokinetics and Tolerability in Subjects With Impaired Renal FunctionThe Journal of Clinical Pharmacology, 2007
- Myocardial perfusion and function single photon emission computed tomographyJournal of Nuclear Cardiology, 2006
- Instrumentation quality assurance and performanceJournal of Nuclear Cardiology, 2006
- Comparative Profile of Vasodilation by CVT-3146, a Novel A2A Receptor Agonist, and Adenosine in Conscious DogsThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Standardized Myocardial Segmentation and Nomenclature for Tomographic Imaging of the HeartCirculation, 2002
- Novel Short-Acting A2A Adenosine Receptor Agonists for Coronary Vasodilation: Inverse Relationship between Affinity and Duration of Action of A2A AgonistsThe Journal of Pharmacology and Experimental Therapeutics, 2001